Medical Oncology | Melanoma | Urological tumours | Immunotherapy

Focus of research
  • Evaluating Immunotherapy in Melanoma: studying biomarkers to predict toxicity and efficacy of immune checkpoint inhibitors in patients with early stage and advanced melanoma.
  • Exploring local regional immunotherapy for melanoma: investigating local regional immuno-stimulating agents (e.g. TLR-receptor agonists, checkpoint inhibitors or cytokines) in early stage melanoma or integrating them in the treatment of advanced melanoma
  • Innovative Clinical Trials: aiming to improve clinical outcomes for patients with melanoma and urological cancers, particularly focusing on the integration of new immunotherapeutic approaches.
  • Monitoring quality of care for patients with melanoma or prostate cancer: investigating real world data to determine the efficacy and safety of new treatments for subgroups of patients with melanoma or prostate cancer.

Fons van den Eertwegh is Professor Clinical Immuno-Oncology at the Amsterdam UMC. He is medical oncologist and Immunologist specialized in the treatment of melanoma and urological tumours. He is recognised for his significant contributions to the field, particularly in the context of melanoma, prostate cancer and immunotherapy.


  • Professor clinical immuno-oncology at the Amsterdam UMC.
  • Member of Dutch Melanoma Skin Cancer Group (DMSCG)
  • Chair if the Dutch Melanoma treatment registry (DMTR)
  • Member of Dutch Society of Medical Oncology (NVMO)
  • Member of European Society of Medical Oncology (ESMO)
  • Member of American Society of Oncology (ASCO)
  • Member of Dutch Society of Immunology (NVVI)
  • Member of Dutch Society of Internal Medicine (NIV)